Raleigh Capital Management Inc. Sells 6,315 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Raleigh Capital Management Inc. reduced its stake in Gilead Sciences by 33.0%, selling 6,315 shares, and now holds 12,820 shares valued at approximately $1.42 million.
• Gilead Sciences announced a dividend of $0.79 per share, representing a 2.8% yield, with a payout ratio of 62.95%.
• The company reported quarterly earnings of $2.01 EPS and revenue of $7.08 billion, surpassing analyst estimates, alongside setting FY 2025 guidance at EPS between 7.950-8.250.

Raleigh Capital Management Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,820 shares of the biopharmaceutical company's stock after selling 6,315 shares during the period. Raleigh Capital Management Inc.'s holdings in Gilead Sciences were worth $1,421,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of GILD. Brighton Jones LLC increased its position in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at about $215,000. Fifth Third Wealth Advisors LLC boosted its stake in Gilead Sciences by 12.8% in the first quarter. Fifth Third Wealth Advisors LLC now owns 13,299 shares of the biopharmaceutical company's stock valued at $1,490,000 after buying an additional 1,505 shares in the last quarter. Mechanics Bank Trust Department boosted its stake in Gilead Sciences by 51.8% in the first quarter. Mechanics Bank Trust Department now owns 10,260 shares of the biopharmaceutical company's stock valued at $1,150,000 after buying an additional 3,500 shares in the last quarter. Finally, Douglas Lane & Associates LLC acquired a new stake in Gilead Sciences in the first quarter valued at about $278,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $112.62 on Tuesday. The business's 50-day moving average price is $114.50 and its 200-day moving average price is $109.90. Gilead Sciences, Inc. has a 12 month low of $82.82 and a 12 month high of $121.83. The firm has a market capitalization of $139.74 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 0.76 and a beta of 0.36. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period last year, the firm posted $2.01 earnings per share. The business's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research note on Tuesday, August 19th. Finally, Rothschild & Co Redburn lifted their price target on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $117.17.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company's stock, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $8,285,530 in the last ninety days. Insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.